Literature DB >> 29309565

It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease.

Lieven Pouillon1,2, Laurent Peyrin-Biroulet1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29309565     DOI： 10.1093/ecco-jcc/jjx174

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

Review 1.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

2.  Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design.

Authors:  Christopher J Tyler; Mauricio Guzman; Luke R Lundborg; Shaila Yeasmin; Tamara Perez-Jeldres; Andres Yarur; Brian Behm; Parambir S Dulai; Derek Patel; Giorgos Bamias; Jesús Rivera-Nieves
Journal:  J Crohns Colitis       Date:  2020-10-05       Impact factor: 9.071

Review 3.  Biologic therapies for Crohn's disease: optimising the old and maximising the new.

Authors:  Mark Samaan; Samantha Campbell; Georgina Cunningham; Aravind Gokul Tamilarasan; Peter M Irving; Sara McCartney
Journal:  F1000Res       Date:  2019-07-29

4.  Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.

Authors:  Francisco Guilherme Cancela E Penna; Rodrigo Macedo Rosa; Pedro Ferrari Sales da Cunha; Stella Cristina Silva de Souza; Maria de Lourdes de Abreu Ferrari
Journal:  BMC Gastroenterol       Date:  2020-02-13       Impact factor: 3.067

5.  Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.

Authors:  Walter Reinisch; Remo Panaccione; Peter Bossuyt; Filip Baert; Alessandro Armuzzi; Xavier Hébuterne; Simon Travis; Silvio Danese; William J Sandborn; Stefan Schreiber; Sofie Berg; Qian Zhou; Kristina Kligys; Ezequiel Neimark; Ahmed A Suleiman; Geert D'Haens; Jean-Frederic Colombel
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.